Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Advance directives in patients with advanced cancer receiving active treatment: attitudes, prevalence, and barriers.

McDonald JC, du Manoir JM, Kevork N, Le LW, Zimmermann C.

Support Care Cancer. 2017 Feb;25(2):523-531. doi: 10.1007/s00520-016-3433-6. Epub 2016 Oct 7.

PMID:
27718068
2.

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.

du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):904-16.

3.

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

Bocci G, Man S, Green SK, Francia G, Ebos JM, du Manoir JM, Weinerman A, Emmenegger U, Ma L, Thorpe P, Davidoff A, Huber J, Hicklin DJ, Kerbel RS.

Cancer Res. 2004 Sep 15;64(18):6616-25.

4.

Variability of neutrophil and pulmonary alveolar macrophage function in swine.

du Manoir JM, Albright BN, Stevenson G, Thompson SH, Mitchell GB, Clark ME, Caswell JL.

Vet Immunol Immunopathol. 2002 Oct 28;89(3-4):175-86.

PMID:
12383649

Supplemental Content

Loading ...
Support Center